Unión Europea - inglés - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - antineoplastic agents - temozolomide sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Canadá - inglés - Health Canada

athena pharmaceutiques sas - ondansetron - tablet (orally disintegrating) - 4mg - ondansetron 4mg - 5-ht3 receptor antagonists

Canadá - inglés - Health Canada

athena pharmaceutiques sas - ondansetron - tablet (orally disintegrating) - 8mg - ondansetron 8mg - 5-ht3 receptor antagonists

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - levetiracetam - solution for infusion - 100mg/1ml

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 5mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 100mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 140mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 180mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 20mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - temozolomide - capsule - 250mg